Magazine Article | October 2, 2023

Companies To Watch: Spruce Biosciences

Source: Life Science Leader

By Wayne Koberstein, Executive Editor, Life Science Leader
Follow Me On Twitter @WayneKoberstein

New agents versus rare endocrine disorders

Spruce Biosciences is currently in mid-to-late-stage clinical development with the CRF1 receptor antagonist, tildacerfont, for treating two endocrine disorders: classic congenital adrenal hyperplasia (CAH) in adults and in children, and polycystic ovary syndrome (PCOS). Tildacerfont is an oral nonsteroidal small-molecule drug. Spruce has long-range plans for additional agents and indications in the same area.

access the Magazine Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.

Subscribe to Life Science Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Life Science Leader